ESPRGuidelinesglobenewswire

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Sentiment:Positive (80)

Summary

(NASDAQ:ESPR) – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 29, 2025 by globenewswire

    Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias | ESPR Stock News | Candlesense